Evidence

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

June 12, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and…

Read more